Assessing the Association of Mitochondrial Genetic Variation With Primary Open-Angle Glaucoma Using Gene-Set Analyses by Khawaja, Anthony P. et al.
Genetics
Assessing the Association of Mitochondrial Genetic
Variation With Primary Open-Angle Glaucoma Using Gene-
Set Analyses
Anthony P. Khawaja,1 Jessica N. Cooke Bailey,2 Jae Hee Kang,3 R. Rand Allingham,4 Michael A.
Hauser,4,5 Murray Brilliant,6 Donald L. Budenz,7 William G. Christen,8 John Fingert,9,10 Douglas
Gaasterland,11 Terry Gaasterland,12 Peter Kraft,13,14 Richard K. Lee,15 Paul R. Lichter,16 Yutao
Liu,17,18 Felipe Medeiros,19 Syoko E. Moroi,16 Julia E. Richards,16,20 Tony Realini,21 Robert
Ritch,22 Joel S. Schuman,23 William K. Scott,24 Kuldev Singh,25 Arthur J. Sit,26 Douglas Vollrath,27
Gadi Wollstein,28 Donald J. Zack,29 Kang Zhang,19 Margaret Pericak-Vance,24 Robert N.
Weinreb,19 Jonathan L. Haines,2 Louis R. Pasquale,3,30 and Janey L. Wiggs30
1National Institute for Health Research (NIHR) Biomedical Research Centre, Moorfields Eye Hospital National Health Service (NHS)
Foundation Trust, and University College London (UCL) Institute of Ophthalmology, London, United Kingdom
2Department of Epidemiology and Biostatistics, Institute for Computational Biology, Case Western Reserve University School of
Medicine, Cleveland, Ohio, United States
3Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United
States
4Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States
5Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States
6Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
7Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
8Division of Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
9Department of Ophthalmology, University of Iowa, College of Medicine, Iowa City, Iowa, United States
10Stephen A. Wynn Institute for Vision Research, Iowa City, Iowa, United States
11The Emmes Corporation, Rockville, Maryland, United States
12Scripps Genome Center, University of California at San Diego, San Diego, California, United States
13Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States
14Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts, United States
15Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States
16Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan, United States
17Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, Georgia, United States
18James and Jean Culver Vision Discovery Institute, Medical College of Georgia, Augusta University, Augusta, Georgia, United States
19Hamilton Glaucoma Center, Shiley Eye Institute, University of California, San Diego, San Diego, California, United States
20Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States
21Department of Ophthalmology, West Virginia University Eye Institute, Morgantown, West Virginia, United States
22Einhorn Clinical Research Center, Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York,
New York, United States
23Department of Ophthalmology, New York University, New York, New York, United States
24Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, United States
25Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
26Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
27Department of Genetics, Stanford University School of Medicine, Palo Alto, California, United States
28Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
29Wilmer Eye Institute, Johns Hopkins University Hospital, Baltimore, Maryland, United States
30Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United
States
iovs.arvojournals.org j ISSN: 1552-5783 5046
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Correspondence: Janey L. Wiggs,
Paul Austin Chandler Professor of
Ophthalmology, Department of
Ophthalmology, Harvard Medical
School, Massachusetts Eye and Ear,
Boston, MA 02114, USA;
janey_wiggs@meei.harvard.edu.
Submitted: May 27, 2016
Accepted: July 27, 2016
Citation: Khawaja AP, Cooke Bailey JN,
Kang JH, et al. Assessing the
association of mitochondrial genetic
variation with primary open-angle
glaucoma using gene-set analyses.
Invest Ophthalmol Vis Sci.
2016;57:5046–5052. DOI:10.1167/
iovs.16-20017
PURPOSE. Recent studies indicate that mitochondrial proteins may contribute to the
pathogenesis of primary open-angle glaucoma (POAG). In this study, we examined the
association between POAG and common variations in gene-encoding mitochondrial proteins.
METHODS. We examined genetic data from 3430 POAG cases and 3108 controls derived from
the combination of the GLAUGEN and NEIGHBOR studies. We constructed biological-system
coherent mitochondrial nuclear-encoded protein gene-sets by intersecting the MitoCarta
database with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. We
examined the mitochondrial gene-sets for association with POAG and with normal-tension
glaucoma (NTG) and high-tension glaucoma (HTG) subsets using Pathway Analysis by
Randomization Incorporating Structure.
RESULTS. We identified 22 KEGG pathways with significant mitochondrial protein-encoding
gene enrichment, belonging to six general biological classes. Among the pathway classes,
mitochondrial lipid metabolism was associated with POAG overall (P ¼ 0.013) and with NTG
(P ¼ 0.0006), and mitochondrial carbohydrate metabolism was associated with NTG (P ¼
0.030). Examining the individual KEGG pathway mitochondrial gene-sets, fatty acid
elongation and synthesis and degradation of ketone bodies, both lipid metabolism pathways,
were significantly associated with POAG (P ¼ 0.005 and P ¼ 0.002, respectively) and NTG (P
¼ 0.0004 and P < 0.0001, respectively). Butanoate metabolism, a carbohydrate metabolism
pathway, was significantly associated with POAG (P ¼ 0.004), NTG (P ¼ 0.001), and HTG (P
¼ 0.010).
CONCLUSIONS. We present an effective approach for assessing the contributions of
mitochondrial genetic variation to open-angle glaucoma. Our findings support a role for
mitochondria in POAG pathogenesis and specifically point to lipid and carbohydrate
metabolism pathways as being important.
Keywords: glaucoma, genetics, mitochondria
Although raised intraocular pressure (IOP) is a key riskfactor for primary open-angle glaucoma (POAG), only a
fraction of individuals with elevated IOP develop POAG, and
approximately one-third of Caucasian (European ancestry)
POAG patients have normal IOP levels (normal-tension
glaucoma [NTG]) suggesting that other factors can influence
susceptibility to optic nerve degeneration. There is growing
evidence for mitochondrial dysfunction in optic nerve
susceptibility to glaucoma.1–4 The characteristic visual field
loss seen in glaucoma locates the site of retinal ganglion cell
(RGC) injury to the optic nerve head. RGC axons coursing
through the retina and into the prelaminar cribrosa optic nerve
are not myelinated, providing the necessary transparency to
incident light on its route to the retinal photoreceptors. This
unmyelinated axonal segment represents the longest node of
Ranvier in the body and to sustain action potentials is endowed
with an ample supply of mitochondria necessary to generate
sufficient adenosine triphosphate (ATP) to sustain action
potential propagation in the absence of myelin.5 Because of
this high energy requirement, the optic nerve head is a region
that is particularly susceptible to mitochondrial dysfunction.
For example, RGC loss or dysfunction is a feature of diseases
caused by mitochondrial DNA mutations, including Leber’s
hereditary optic neuropathy and is also a common manifesta-
tion of many other mitochondrial disease syndromes.5 Mito-
chondrial dysfunction has been increasingly shown to play a
role in other age-related neurodegenerative conditions such as
Parkinson’s disease and Alzheimer’s disease.6
Genetic studies have suggested that nuclear genes encoding
mitochondrial proteins may contribute to POAG risk.7 Recent-
ly, a large genome-wide association study identified significant
association of POAG with single nucleotide polymorphisms
(SNPs) in the TXNRD2 genomic region, a nuclear-encoded
mitochondrial protein that functions to maintain redox
homeostasis.4 In this study, we examined the association
between genetic variation in a comprehensive set of nuclear-
encoded mitochondrial proteins and POAG in a large case-
control dataset. We conducted gene-set analyses of mitochon-
dria-enriched biological pathways, examining the association




We examined genetic data from 3430 POAG cases and 3108
controls derived from the combination of the Glaucoma Genes
and Environment (GLAUGEN) and NEI Glaucoma Human
Genetics collaBORation (NEIGHBOR) studies.8,9 A meta-analy-
sis of the Genome-Wide Association Studies (GWAS) for POAG
from these two studies has been previously published,10 and
the results of this meta-analysis have been used for the analyses
conducted in this study. Detailed methods for participant
recruitment and the GWAS have been described.8–10 In brief,
GLAUGEN consists of participants from two cohort studies, the
Health Professionals Follow-up Study and the Nurses’ Health
Study, and one clinic-based study from the Massachusetts Eye
and Ear Infirmary; NEIGHBOR consists of participants from 12
clinic-based studies in the United States. The research followed
the Declaration of Helsinki and was approved by the
institutional review boards of the Brigham and Women’s
Hospital; Duke University; Harvard T.H. Chan School of Public
Health; Johns Hopkins University; the Marshfield Clinic;
Massachusetts Eye and Ear Infirmary; Stanford University;
University of California, San Diego; University of Miami;
University of Michigan; University of Pittsburgh; and University
of West Virginia. All participants provided written informed
consent and all participants were Caucasians with European
ancestry. Primary open-angle glaucoma cases were required to
have visual field defects consistent with nerve fiber layer
pathology, open angles, and no other significant findings on
slit-lamp examination. Intraocular pressure was not part of the
case definition, which allowed subgroup analyses of normal
tension POAG (NTG, highest known screening IOP < 22 mm
Hg) and high-tension POAG (HTG, history of IOP ‡ 22 mm Hg)
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in those participants with IOP data available. Visual field loss
was required to be reproduced in the same region on a
subsequent test, or if these data were not available, then the
case definition required signs suggestive of glaucomatous optic
neuropathy, namely a vertical cup-to-disc ratio > 0.7. Control
participants were required to have a vertical cup-to-disc ratio <
0.6 and IOP < 22 mm Hg as evidenced at an eye examination
during the 2 years prior to study enrollment.
Genotyping and Association Analysis
The Illumina Human 660WQuadv1C BeadChip array (Illumina,
San Diego, CA, USA) was used to genotype all participants.
GLAUGEN study samples were processed at the Broad Institute
(Cambridge, MA, USA), and NEIGHBOR samples were pro-
cessed at the Center for Inherited Disease Research (Baltimore,
MD, USA). Details regarding data cleaning and quality control
have been published previously.10 The association analyses of
genotypes with POAG were carried out with logistic regression
assuming an additive model using PLINK v1.07 (http://pngu.
mgh.harvard.edu/~purcell/plink/, in the public domain).11
Analyses were conducted separately for GLAUGEN and
NEIGHBOR (genomic inflation factors were 1.009 and 1.034,
respectively) and then meta-analyzed, weighting by inverse
variance using METAL.12 GLAUGEN analyses were adjusted for
age, sex, study site, DNA source, DNA extraction method, and
three principal components; NEIGHBOR analyses were adjust-
ed for age, sex, study site, and two principal components.
Defining the Mitochondriome and Mitochondria-
Enriched Biological Pathways
The mitochondrial proteome consists of more than 1000
proteins, only 13 of which are encoded by mitochondrial
DNA; the vast majority of proteins that are important for
mitochondrial structure and function are encoded by nuclear
DNA.13 For the purpose of the current study, we confined our
analysis to nuclear genes encoding the mitochondrial proteome
because the platform used for genotyping does not include a
sufficient number of mitochondrial DNA variants for analysis
using pathway software programs, including the program
Pathway Analysis by Randomization Incorporating Structure
(PARIS; http://csg.sph.umich.edu/abecasis/metal/index.html, in
the public domain) used for this study.14 We identified 1010
nuclear-encoded mitochondria genes using the Human Mito-
Carta database (www.broadinstitute.org/pubs/MitoCarta, in the
public domian)15 and refer to these genes as the mitochon-
driome (Supplementary Fig. S1). In addition to the production
of ATP by oxidative phosphorylation, mitochondria are essential
for a diverse range of biological processes, and different genes in
the mitochondriome may be responsible for contrasting
biological pathways. We therefore identified subsets of the
mitochondriome that were important for different biological
pathways by intersecting the Human MitoCarta database with
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
biological pathway database (version 58.1).16 We considered
KEGG pathways to have a significant mitochondrial component
if the gene enrichment P value of the MitoCarta genes in the
overall pathway was significant using the hypergeometric test
with Bonferroni correction (209 pathways yielded a significance
threshold of 2.43 104).
Mitochondria-Enriched Biological Pathway
Analyses
For each mitochondria-enriched biological pathway we iden-
tified, we defined a gene-set that consisted of only the
MitoCarta genes within the pathway, aiming to represent the
mitochondrial component of the biological process. We tested
for association between these gene-sets and POAG overall,
NTG and HTG using PARIS (version 1.1.1).14 An advantage of a
pathway or gene-set approach is that variants of smaller effect
sizes that individually did not meet strict multiple comparison
criteria for genome-wide association may in aggregate show
significant association with disease as a result of the overall
effect of the cumulative variation of a pathway or set of genes.
The approach used by PARIS has been described in detail
previously14 and has been used successfully for examining the
association between the estrogen metabolism pathway and
POAG17 as well as for examining the association of all KEGG
pathways with POAG.18 Briefly, PARIS divides the specified
gene-set into linkage disequilibrium (LD) blocks, and randomly
selects similarly sized LD blocks from the rest of the genome
for comparison. The number of LD blocks with at least one
SNP significant at P < 0.05 is compared between the gene-set
in question and the randomly selected set of LD blocks. This
process is repeated a user-defined number of times (we
completed 10,000 permutations per test), and a permuted P
value is calculated based on the number of times the gene-set
in question had more significant LD blocks than the randomly
selected comparison.
PARIS also calculates gene P values by repeating the
randomization and permutation process using just the LD
blocks within each gene. Single nucleotide polymorphisms
from the GWAS were considered to reside in a pathway gene if
the SNP fell within the ENSEMBL genomic interval 650 kb to
either side of the gene. If the overlap included another gene in
the pathway, the overlapping SNP(s) were counted once.
Examining gene P values helps identify which parts of a larger
pathway are driving an association. However, caution is
required when interpreting gene P values, especially if only a
small number of LD blocks are represented by the gene.14
Consider an extreme example of a gene with just one LD block,
and that LD block has a SNP P < 0.05. PARIS will always
produce a significant gene P value for such genes. We therefore
only examined gene P values for genes represented by at least
five LD blocks from our genotyping data.
We set a threshold for a single-allele P value of <0.05 as
nominally significant for use within the PARIS analysis and used
a permutation test of 10,000 permutations to determine the
significance of the pathway analyses. A KEGG pathway was
considered to be significant at the P < 0.0001 level if none of
the 10,000 randomized pathways had more significant SNP
signals than the actual pathway.
RESULTS
We examined genetic data from 3,430 POAG cases (mean age
65.2 years, 54% women) and 3,108 controls (mean age 67.5
years, 56% women). For these cases, IOP data were available
from 2354 participants (67%); 717 were classified as NTG and
1637 as HTG.
We identified 22 KEGG pathways with significant mito-
chondrial gene enrichment, belonging to six pathway classes:
amino acid metabolism, carbohydrate metabolism, energy
metabolism, lipid metabolism, metabolism of cofactors and
vitamins, and nucleotide metabolism (Table 1). Pathway-
specific mitochondrial gene-sets were created using these
data; 6 gene-sets relating to the pathway classes and 22 gene-
sets relating to the individual pathways within the classes
(Supplementary Table S1). We excluded genes not present in
the Human MitoCarta database from the gene sets.
Table 2 presents the results of an examination of the
associations between the six main pathway class gene-sets and
POAG, NTG, and HTG using PARIS. The mitochondrial gene-set
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involved in lipid metabolism was nominally associated with
POAG overall (P ¼ 0.013); this association appeared to be
driven by a significant association with NTG (P¼0.0006), with
no significant association seen with HTG (P¼ 0.15). A nominal
association was also observed between the carbohydrate
metabolism mitochondrial gene-set and NTG and the nucleo-
tide metabolism gene-set (that includes TXNRD2) with POAG
overall (both P < 0.05).
Table 3 presents the associations for the 22 individual KEGG
pathway-defined mitochondrial gene-sets and POAG, NTG, and
HTG. As expected, some lipid metabolism class gene-sets were
significantly associated with POAG, and particularly with NTG.
Specifically, the mitochondrial components of fatty acid
elongation and synthesis and degradation of ketone bodies
were significantly associated with POAG overall (P¼ 0.005 and
P¼ 0.002), and significantly associated with NTG (P¼ 0.0004
and P < 0.0001). The mitochondrial component of fatty acid
metabolism was nominally associated with POAG overall (P ¼
0.023). There was also evidence of association between the
carbohydrate metabolism class gene-sets and NTG, especially
the butanoate metabolism gene-set, which was significantly
associated with NTG (P ¼ 0.001) in addition to an interesting
association between NTG and propanoate metabolism (P ¼
0.002) and pyruvate metabolism (P ¼ 0.01).
We examined the component gene P values for the lipid
metabolism and carbohydrate metabolism gene-sets (Supple-
mentary Tables S2, S3). Genes driving both lipid and
carbohydrate metabolism associations with POAG and NTG
were BDH1 (POAG and NTG P < 0.0001), EHHADH (POAG P
¼ 0.044, NTG P¼ 0.0009), and ECHS1 (POAG P¼ 0.004, NTG
P ¼ 0.002). In addition, ACAA2 (POAG P ¼ 0.024, NTG P ¼
0.0008) from the lipid metabolism gene-set and ME3 (POAG P
¼ 0.0003, NTG P ¼ 0.30), ACYP2 (POAG P ¼ 0.001, NTG P ¼
0.43), LDHD (POAG P ¼ 1.00, NTG P ¼ 0.004), and LDHB
(POAG P ¼ 1.00, NTG P ¼ 0.003) from the carbohydrate
metabolism gene-set were significantly associated with POAG
and/or NTG. The gene P values for TXNRD2 were significant
for an association with POAG overall (P < 0.001).
DISCUSSION
In this large case-control study, we demonstrated significant
associations between POAG and groups of nuclear genes
important for specific aspects of mitochondrial function,
namely, lipid metabolism (fatty acid elongation and synthesis
and degradation of ketone bodies) and carbohydrate metabo-
TABLE 1. KEGG Pathways With Significant Enrichment of MitoCarta Genes











Oxidative phosphorylation Energy metabolism hsa00190 132 93 (70) 1.05E-90
Valine, leucine, and isoleucine degradation Amino acid metabolism hsa00280 44 39 (89) 7.27E-46
Citrate cycle (TCA cycle) Carbohydrate metabolism hsa00020 31 30 (97) 1.76E-38
Propanoate metabolism Carbohydrate metabolism hsa00640 32 28 (88) 7.42E-33
Fatty acid metabolism Lipid metabolism hsa00071 44 29 (66) 1.33E-27
Pyruvate metabolism Carbohydrate metabolism hsa00620 41 28 (68) 2.32E-27
Butanoate metabolism Carbohydrate metabolism hsa00650 30 21 (70) 3.48E-21
Arginine and proline metabolism Amino acid metabolism hsa00330 55 25 (45) 1.50E-18
Glycine, serine, and threonine metabolism Amino acid metabolism hsa00260 32 18 (56) 7.54E-16
Tryptophan metabolism Amino acid metabolism hsa00380 42 19 (45) 2.23E-14
Glyoxylate and dicarboxylate metabolism Carbohydrate metabolism hsa00630 18 12 (67) 3.10E-12
Lysine degradation Amino acid metabolism hsa00310 49 17 (35) 8.52E-11
One carbon pool by folate Metabolism of cofactors and
vitamins
hsa00670 18 11 (61) 1.02E-10
beta-Alanine metabolism Metabolism of other amino acids hsa00410 27 12 (44) 1.84E-09
Valine, leucine, and isoleucine biosynthesis Amino acid metabolism hsa00290 11 8 (73) 5.34E-09
Alanine, aspartate, and glutamate metabolism Amino acid metabolism hsa00250 32 12 (38) 1.86E-08
Fatty acid elongation Lipid metabolism hsa00062 8 6 (75) 3.87E-07
Porphyrin and chlorophyll metabolism Metabolism of cofactors and
vitamins
hsa00860 43 12 (28) 7.22E-07
Pyrimidine metabolism Nucleotide metabolism hsa00240 100 18 (18) 1.59E-06
Fatty acid biosynthesis Lipid Metabolism hsa00061 6 5 (83) 1.76E-06
Ubiquinone and other terpenoid-quinone
biosynthesis
Metabolism of cofactors and
vitamins
hsa00130 7 5 (71) 5.84E-06
Synthesis and degradation of ketone bodies Lipid metabolism hsa00072 9 5 (56) 3.16E-05
KEGG pathway ID and class are presented as well as the total number of genes in the KEGG pathway and the proportion of genes that are listed
in the Human MitoCarta database. Pathways are in descending order of mitochondrial enrichment. ID, identification; TCA, tricarboxylic acid.
TABLE 2. Associations Between the Six Main Pathway Class Mitochon-
drial Gene-Sets and Primary Open-Angle Glaucoma (POAG, 3430
Cases), Normal Tension Glaucoma (NTG, 717 Cases), and High Tension






Amino acid metabolism 0.76 0.12 0.86
Carbohydrate metabolism 0.05 0.030 0.20
Energy metabolism 0.60 0.15 0.09
Lipid metabolism 0.013 0.0006 0.15
Metabolism of cofactors and vitamins 0.56 0.97 0.65
Nucleotide metabolism 0.025 0.77 0.10
Permuted P values were derived from 10,000 cycles of the PARIS
software. Bold text indicates P values < 0.05.
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lism (butanoate metabolism). These associations were partic-
ularly apparent for the NTG subgroup.
Mitochondria serve many diverse biological roles, including
generation of ATP, cellular homeostasis, signaling, neuronal
excitability, and apoptosis.19 Challenges exist in examining the
role of mitochondria in disease. It seems likely that for any
particular disease, only specific mitochondrial functions may
impact disease pathogenesis. For example, oxidative phos-
phorylation was notably not associated with POAG in our study
despite being the pathway with the greatest nuclear-encoded
mitochondrial gene enrichment. In our study, we present an
effective approach to examining the role of mitochondria in
disease by using variation in the mitochondriome as a proxy for
mitochondrial function. After dividing the mitochondriome
into biological system coherent gene-sets and examining each
gene-set for collective association with disease, we demon-
strated a significant association between POAG and mitochon-
drial gene-sets that are involved in lipid and carbohydrate
metabolism. Our results were especially significant in the NTG
subgroup, suggesting that the observed association is more
likely to influence optic nerve susceptibility rather than
elevated IOP.
The mechanisms by which mitochondrial impairment in
these pathways may contribute to glaucoma are not clear,
although our results suggest that they may be related to fatty
acid metabolism and elongation, synthesis and degradation of
ketone bodies, and butanoate and pyruvate metabolism. The
association of the whole butanoate KEGG pathway (including
nonmitochondrial genes) with POAG in our study population
has been previously reported.18 Genes in the butanoate
metabolism pathway contribute to the formation of 4-amino-
butanoate (GABA). GABA plays an important role in the visual
response, and the inhibition of GABA transaminase by the
antiepileptic medication vigabatrin can result in visual field
defects.20 Our gene-set analysis results are in agreement with a
study that examined 65 candidate POAG genes using the
Ingenuity knowledge database (www.ingenuity.com, in the
public domain); the investigators reported that the genes take
part in only four common functional molecular networks
corresponding to lipid metabolism, developmental function,
and inflammatory processes.21 Also consistent with our
findings is a GWAS of NTG in Japanese patients that found an
interesting association with ELOVL5, a gene involved in long-
chain polyunsaturated fatty acid synthesis.22 Abnormal lip-
id23,24 and carbohydrate25 metabolism has been demonstrated
in glaucomatous eyes, as observed in the trabecular meshwork
and aqueous humor. These data are consistent with our
pathway analysis data, although our results are stronger with
NTG rather than POAG overall or HTG. Our study also
identified nominal association with the pyrimidine pathway
that includes TXNRD2, coding for a mitochondrial protein
involved in managing mitochondrial oxidative stress. A KEGG
pathway specifically including mitochondrial redox homeosta-
sis proteins does not exist and therefore could not be evaluated
in this study.
Using PARIS to evaluate individual constituent genes of a
pathway helps identify any genes associated with the outcome,
which may be the main drivers of the entire pathway
association. We found strong signals of association with POAG
for BDH1, EHHADH, ACAA2, and ME3. These genes have not
been previously reported to be associated with POAG in other
studies, and further work seeking replication of the associa-
tions in other populations would be of interest.
Our results could have important implications for future
study of the role of mitochondria in the pathogenesis of
glaucoma. Patients with an excess of risk alleles influencing
mitochondrial proteins could have a unique natural history
when compared with POAG overall and may have a different
response to treatment. Resveratrol, caloric restriction, and
physical activity have been suggested as interventions to
improve mitochondrial function, and evidence exists for
potential benefit in animal models of retinal ischaemia and
acute intraocular pressure injury.26–28 One approach to
identifying POAG patients with a mitochondrial component
to their disease would be a genetic analysis of their
mitochondriome. A genetic risk score (GRS) based on these
gene-set analyses could be used in future studies to investigate
the phenotypic features of glaucoma patients with an excess of
mitochondrial risk variants. The GRS could also be used to
examine interactions with other genetic or environmental
factors. For example, no effect of dietary antioxidants was
found on the development of POAG in a subset of the current
study29; it would be of interest to know if an effect is evident
TABLE 3. Associations Between KEGG Pathway-Defined Mitochondrial
Gene-Sets and Primary Open-Angle Glaucoma (POAG, 3430 Cases),
Normal Tension Glaucoma (NTG, 717 Cases), and High Tension







Alanine, aspartate, and glutamate
metabolism 0.18 0.33 0.17
Arginine and proline metabolism 0.43 0.08 0.94
Glycine, serine, and threonine
metabolism 0.26 0.94 0.83
Lysine degradation 0.13 0.10 0.20
Tryptophan metabolism 0.18 0.14 0.36
Valine, leucine, and isoleucine
biosynthesis 0.98 0.04 0.51
Valine, leucine, and isoleucine
degradation 0.60 0.35 0.23
Carbohydrate metabolism
Butanoate metabolism 0.004 0.0011 0.010
Citrate cycle (TCA cycle) 0.74 0.99 0.73
Glyoxylate and dicarboxylate
metabolism 0.73 0.69 0.72
Propanoate metabolism 0.67 0.002 0.42
Pyruvate metabolism 0.006 0.011 0.05
Energy metabolism
Oxidative phosphorylation 0.60 0.15 0.09
Lipid metabolism
Fatty acid biosynthesis 0.83 0.12 0.65
Fatty acid elongation 0.005 0.0004 0.23
Fatty acid metabolism 0.023 0.12 0.29
Synthesis and degradation of
ketone bodies 0.002 <0.0001 0.021
Metabolism of cofactors and vitamins
One carbon pool by folate 0.57 0.86 0.31
Porphyrin and chlorophyll
metabolism 0.29 0.87 0.78
Ubiquinone and other terpenoid-
quinone biosynthesis 0.58 0.56 0.57
beta-Alanine metabolism 0.07 0.03 0.20
Nucleotide metabolism
Pyrimidine metabolism 0.025 0.77 0.10
Permuted P values were derived from 10,000 cycles of the PARIS
analyses. Bold text indicates P values < 0.05.
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when only examining participants with a high mitochondrial
GRS score, especially considering the potential contributions
of TXNRD2.
A significant strength of our study is the large sample size
and number of POAG cases (both HTG and NTG), which
provided the necessary power for our analyses. Our approach
of testing mitochondrial genes in biological system groups
collectively is novel and appears to be a useful method for
probing specific hypotheses. There are some limitations to our
approach. The completeness and accuracy of the gene-sets we
tested were limited by the completeness of the MitoCarta and
KEGG databases and current knowledge. We did not consider
variation in mitochondrial DNA because of limited information
for mitochondrial DNA variants in our genotype data. However,
mitochondria DNA encode only 13 proteins and therefore
represents a minor fraction of the overall mitochondrial
proteome. Nevertheless, further study of mitochondrial DNA
variants in glaucoma is warranted using other datasets. It is also
not currently possible to replicate our findings in another
population; our strongest findings were in NTG patients and
there are no other similarly sized Caucasian NTG case-control
datasets with genetic data available. Further work is required to
determine the precise role of the pathways and genes we
described in POAG.
In summary, we present evidence supporting a role for
mitochondria in POAG pathogenesis. Specifically, genes
encoding mitochondrial proteins that are involved in lipid
and carbohydrate metabolism were found to be associated
with POAG, and in particular NTG. Future studies stratifying
POAG patients according to genetic variation in mitochondrial
genes may help identify a pathologically distinct POAG subset
related to mitochondrial dysfunction.
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